PODCAST

Breast Cancer and Breast Health

ReachMD

science & medicine medicine

All Episodes

00:00:00

Chairperson Perspective: Improving HR+/HER2- Breast...

Breast Cancer and Breast Health ·

2025/04/18

Host: Aditya Bardia, MD, MPH The recent approvals of therapies for hormone-receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) have augmented the treatment armamentarium in this setting, giving clinicians more options for their patients. However, it may be challenging to select the optimal therapy for individual patients. Moreover, it is important to differentiate between the 2 available TROP2-directed antibody-drug conjugates (ADCs). This activity reviews

00:00:00

Differentiating Agents in the Expanding HER2-Targeted...

Breast Cancer and Breast Health ·

2025/02/06

Guest: Carey Anders, MD, FASCO Guest: Sarah Sammons, MD The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review

00:00:00

HER2-Targeted TKI Combinations in Second-Line and...

Breast Cancer and Breast Health ·

2025/02/06

Guest: Sarah Sammons, MD The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing

00:00:00

Understanding CNS Lesions in HER2+ Metastatic Breast...

Breast Cancer and Breast Health ·

2025/02/06

00:00:00

Systemic Management of Brain Metastases in HER2+ BC:...

Breast Cancer and Breast Health ·

2025/02/06

Guest: Carey Anders, MD, FASCO The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing

00:00:00

Optimizing Treatment Selection for HER2+ Breast...

Breast Cancer and Breast Health ·

2025/02/06

00:00:00

Sequencing Strategies for Second-Line and Beyond...

Breast Cancer and Breast Health ·

2025/02/06

Guest: Sarah Sammons, MD Guest: Carey Anders, MD, FASCO The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review

00:00:00

Leveraging Clinical Data: HER2-Targeted ADCs in...

Breast Cancer and Breast Health ·

2025/02/06

00:00:00

Virtual Tumor Board: Maximizing the Potential of...

Breast Cancer and Breast Health ·

2025/02/05

Guest: Heather McArthur, MD Guest: Margaret Gatti-Mays, MD, MPH Tune in for a deep dive into the evolving landscape of immuno-oncology (IO) in early-stage triple-negative breast cancer (TNBC). Our experts focus on identifying eligible patients for neoadjuvant and adjuvant IO regimens, understanding current and emerging treatment options, and effectively utilizing shared decision-making (SDM) techniques to tailor treatment plans. The activity also covers the importance of

00:00:00

Targeting HER3 in Breast and Lung Cancers: Where We...

Breast Cancer and Breast Health ·

2023/05/15

Host: Jennifer Caudle, DO Guest: Sara A. Hurvitz, MD, FACP Guest: Narjust Florez, MD This CME-accredited podcast explores the rationale for targeting human epidermal growth factor receptor 3 (HER3) in non–small cell lung cancer (NSCLC) and breast cancer. It includes an in-depth discussion of the mechanism of action, safety, and efficacy of agents that are being investigated to target HER3. The latest results from clinical trials investigating monoclonal antibodies, bispecific

00:00:00

The Oncogenic Significance – and Promise – of HER3 in...

Breast Cancer and Breast Health ·

2023/04/25

Host: Helena Yu, MD Guest: Makenzi Evangelist, MD This Expert Exchange webcast is designed to enhance clinicians’ awareness of the function and role of HER3 in emerging treatment strategies for non-small cell lung cancer and metastatic breast cancer.

00:00:00

Better Early Than Late: CDK4/6 Inhibition in HR +,...

Breast Cancer and Breast Health ·

2023/04/19

Host: Hope S. Rugo, MD, FASCO Guest: Peter Schmid, FRCP, MD, PhD HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationally for the treatment of HR+/HER2- early breast cancer, it’s important to keep up with the latest data for its use. Listen in so Drs. Hope Rugo and Peter Schmid can keep you up to date on the most effective ways to treat your patients.

12 results

Breast Cancer and Breast Health

All Episodes

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事